hVEGFA/hPD-1/hPD-L1

品系全名

C57BL/6JSmo-Vegfatm1(hVEGFA)Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)Smoc

目录号

NM-XA-242143

品系状态

活体

导出PDF

品系描述

通过hPD-1/hPD-L1(NM-HU-00100)与hVEGFA(NM-HU-2000028)小鼠交配获得。

验证数据

image.png

Fig.1 Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (n=8). (A）Body weight. (B) Body weight change.

image.png

Fig.2 Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. (A) Tumor volume. (B) Relative tumor volume.

MC38-hVEGFA (1×106) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (male, 8-week-old, n=8). 

image.png

Fig.3 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human VEGFA expression in MC38-hVEGFA/hPD-L1 tumor by ELISA (n=2). 

image.png

Fig.4 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human PD-L1 expression in MC38-hVEGFA/hPD-L1 tumor by FACS (n=2).

image.png

Fig.5 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A）Body weight. (B) Body weight change.

image.png

Fig.6 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. MC38-hVEGFA/hPD-L1 (1×106) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A) Tumor volume. (B) Relative tumor volume.

image.png

Fig.7 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Flow cytometry analysis of tumor-infiltrating lymphocytes (TILs) from MC38-hVEGFA/hPD-L1 tumor by FACS. Tumor-infiltrating lymphocytes (TILs) were collected to carry out an immunophenotypic analysis by flow cytometry (n=4). According to flow cytometric analysis, post-treatment led to a significant increase in the proportion of T cells, and a substantial reduction in the proportion of myeloid cells.


你也可能感兴趣

Tamoxifen诱导Cre-ERT2小鼠 使用指南

Cre-ERT2在无Tamoxifen诱导的情况下，在细胞质内处于无活性状态；当Tamoxifen诱导后，Tamoxifen的代谢产物4-OHT（雌激素类似物）与ERT结合，可使Cre-ERT2进核发挥Cre重组酶活性。

查看

【小鼠大学问】基因工程小鼠的命名规则

常见的基因工程小鼠可以分为两种命名方式，包括基因定点修饰的小鼠命名，比如：敲除、敲入、点突变等等，和随机转基因的小鼠命名。

查看

Cre-lox系统介绍及使用汇总

你一定听说过Cre-lox重组系统，无论你是否直接进行过基因操作。由于Cre-lox系统具有操作简单、重组率高的优点，如今已经成为体内外遗传操作的强有力工具。利用Cre-lox系统，可以在特定细胞、组织或整个生物体，甚至在特定时间点敲除或表达某个基因，实现对特定基因的时空特异性操作，这对基因功能的研究和人类疾病动物模型的建立都具有深刻影响。

查看